COVID-19住院患者急性肾损伤:ISARIC WHO CCP-UK前瞻性多中心队列研究
BACKGROUND: Acute kidney injury (AKI) is common in coronavirus disease 2019 (COVID-19). This study investigated adults hospitalized with COVID-19 and hypothesized that risk factors for AKI would include comorbidities and non-White race.…
要点
- COVID-19住院成人中生化AKI发生率31.5%,KRT使用率2.6%。
- CKD、男性和黑人种族是KRT及生化AKI的主要危险因素。
- AKI严重程度越高,28天死亡风险梯度增加,需密切监测高危患者肾功能和容量状态。
核心结论
- COVID-19住院成人中AKI常见,且与28天死亡风险升高相关。
- 尽管AKI发生率从疫情早期数月下降,高危患者仍应密切监测肾功能和液体状态。
主要发现
- KRT主要危险因素:CKD(aOR 3.41,95%CI 3.06-3.81)、男性(aOR 2.43,95%CI 2.18-2.71)、黑人种族(aOR 2.17,95%CI 1.79-2.63)。
- 生化AKI主要危险因素:入院呼吸频率>30次/分(aOR 1.68,95%CI 1.56-1.81)、CKD(aOR 1.66,95%CI 1.57-1.76)、黑人种族(aOR 1.44,95%CI 1.28-1.61)。
- 28天死亡风险随AKI严重程度梯度升高:1期aOR 1.58(95%CI 1.49-1.67)、2期aOR 2.41(95%CI 2.20-2.64)、3期aOR 3.50(95%CI 3.14-3.91)、KRT aOR 3.06(95%CI 2.75-3.39)。
- AKI发生率在2020年4月达峰,后续下降不能用地塞米松或瑞德西韦的使用解释。
临床怎么用
- 对COVID-19住院患者,尤其合并CKD、男性或黑人种族者,应密切监测肾功能和液体状态。
- AKI严重程度可用于分层28天死亡风险,指导临床监测强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) is common in coronavirus disease 2019 (COVID-19). This study investigated adults hospitalized with COVID-19 and hypothesized that risk factors for AKI would include comorbidities and non-White race. METHODS: A prospective multicentre cohort study was performed using patients admitted to 254 UK hospitals with COVID-19 between 17 January 2020 and 5 December 2020. RESULTS: Of 85 687 patients, 2198 (2.6%) received acute kidney replacement therapy (KRT). Of 41 294 patients with biochemistry data, 13 000 (31.5%) had biochemical AKI: 8562 stage 1 (65.9%), 2609 stage 2 (20.1%) and 1829 stage 3 (14.1%). The main risk factors for KRT were chronic kidney disease (CKD) [adjusted odds ratio (aOR) 3.41: 95% confidence interval 3.06-3.81], male sex (aOR 2.43: 2.18-2.71) and Black race (aOR 2.17: 1.79-2.63). The main risk factors for biochemical AKI were admission respiratory rate >30 breaths per minute (aOR 1.68: 1.56-1.81), CKD (aOR 1.66: 1.57-1.76) and Black race (aOR 1.44: 1.28-1.61). There was a gradated rise in the risk of 28-day mortality by increasing severity of AKI: stage 1 aOR 1.58 (1.49-1.67), stage 2 aOR 2.41 (2.20-2.64), stage 3 aOR 3.50 (3.14-3.91) and KRT aOR 3.06 (2.75-3.39). AKI rates peaked in April 2020 and the subsequent fall in rates could not be explained by the use of dexamethasone or remdesivir. CONCLUSIONS: AKI is common in adults hospitalized with COVID-19 and it is associated with a heightened risk of mortality. Although the rates of AKI have fallen from the early months of the pandemic, high-risk patients should have their kidney function and fluid status monitored closely.
引用
- Sullivan MK, Lees JS, Drake TM, et al. Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrol Dial Transplant. 2022. PMID: 34661677. doi:10.1093/ndt/gfab303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。